
    
      This cross-sectional study evaluates a series of patients with ME due to RVO who were
      available for at least 4 years' follow-up examination. The patients received either
      intravitreal ranibizumab (IVR) or bevacizumab (IVB) in a flexible dosing regimen
    
  